These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 28965955

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
    Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M.
    BMJ; 2019 Apr 03; 365():l1161. PubMed ID: 30944092
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, Garland SM, Chen MY, Fairley CK.
    Lancet Infect Dis; 2017 Jan 03; 17(1):68-77. PubMed ID: 27282422
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.
    Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M.
    Br J Cancer; 2014 May 27; 110(11):2804-11. PubMed ID: 24736582
    [Abstract] [Full Text] [Related]

  • 8. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.
    Feiring B, Laake I, Christiansen IK, Hansen M, Stålcrantz J, Ambur OH, Magnus P, Jonassen CM, Trogstad L.
    J Infect Dis; 2018 Nov 05; 218(12):1900-1910. PubMed ID: 30010913
    [Abstract] [Full Text] [Related]

  • 9. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
    Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, Ahmed S, Palmer T, Pollock KG.
    Emerg Infect Dis; 2016 Jan 05; 22(1):56-64. PubMed ID: 26692336
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
    Hoes J, Woestenberg PJ, Bogaards JA, King AJ, de Melker HE, Berkhof J, Hoebe CJPA, van der Sande MAB, van Benthem BHB, Medical Microbiological Laboratories and Public Health Services.
    Clin Infect Dis; 2021 Mar 01; 72(5):e103-e111. PubMed ID: 33249475
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
    Sayinzoga F, Tenet V, Heideman DAM, Sibomana H, Umulisa MC, Franceschi S, Hakizimana JD, Clifford GM, Baussano I.
    Lancet Glob Health; 2023 Jul 01; 11(7):e1096-e1104. PubMed ID: 37207683
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
    Latsuzbaia A, Arbyn M, Tapp J, Fischer M, Weyers S, Pesch P, Mossong J.
    Cancer Epidemiol; 2019 Dec 01; 63():101593. PubMed ID: 31499377
    [Abstract] [Full Text] [Related]

  • 14. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
    Covert C, Ding L, Brown D, Franco EL, Bernstein DI, Kahn JA.
    Hum Vaccin Immunother; 2019 Dec 01; 15(7-8):1962-1969. PubMed ID: 30633598
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease.
    Cameron RL, Palmer TJ, Cuschieri K, Kavanagh K, Roy K.
    Vaccine; 2024 Aug 30; 42(21):126177. PubMed ID: 39128198
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.